How EDS and Hypermobility Are Diagnosed: The Beighton Score, the 2017 Criteria, and What a Test Can't Tell You

Short Answer

There isn't one "EDS test" or "hypermobility test" that hands you a diagnosis. The process starts smaller: a clinician first asks whether your joints move farther than expected for your age and body. That screen is often the Beighton score, a 9-point bedside exam of fingers, thumbs, elbows, knees, and forward bending. A quick self-screen can also help, especially if you used to be more flexible than you are now: the validated 5-Part Questionnaire (5PQ). But screening only flags hypermobility — described as "the ability of one or more joints to move beyond the normal range of motion" — not the cause. A positive Beighton score or 5PQ is a reason to look deeper, not a diagnosis by itself (pubmed.ncbi.nlm.nih.gov).

For hypermobile Ehlers-Danlos syndrome (hEDS), the diagnosis is clinical. A clinician applies the 2017 international diagnostic criteria, which have three parts: generalized joint hypermobility; enough supporting features such as systemic connective-tissue signs, family history, or musculoskeletal complications; and exclusion of other diagnoses that could better explain the pattern. The Beighton threshold is age-adjusted: commonly cited as ≥6/9 for prepubertal children and adolescents, ≥5/9 for pubertal people through age 50, and ≥4/9 after age 50 (pubmed.ncbi.nlm.nih.gov). In adults, GeneReviews summarizes the hEDS cutoffs as ≥5 for adolescents who have reached biologic maturity and adults age 50 or younger, and ≥4 for those older than 50. hEDS has no confirming gene test; currently, molecular testing cannot establish the diagnosis (ncbi.nlm.nih.gov).

For other EDS subtypes, genetics works differently. The 2017 international classification states that the definite diagnosis of every EDS subtype except the hypermobile type relies on molecular confirmation. For example, classic EDS is established with characteristic clinical features plus a pathogenic variant in genes such as COL5A1, COL5A2, or COL1A1, while vascular EDS is established by a pathogenic variant in COL3A1. That is why "EDS testing" can mean very different things: a clinical criteria visit for suspected hEDS, genetic testing for many other EDS types, or a hypermobility screen that simply tells you whether your joints are unusually flexible (pubmed.ncbi.nlm.nih.gov).

Welltory does not diagnose EDS, hEDS, POTS, or hypermobility, and it is not a diagnostic test. What it can do — if your hypermobility story also includes a racing pulse when you stand, dizziness, crashes after activity, or fatigue — is help you bring a clearer autonomic timeline to your appointment: resting heart rate, HRV patterns, and how your body responds to standing and activity over weeks. That record cannot prove what you have. But it can turn "I feel weird when I stand up" into a pattern your clinician can discuss alongside symptoms, exam findings, Beighton scoring, and, when appropriate, referral for genetics or autonomic testing. Cardiovascular autonomic dysfunction is commonly described in hEDS, and studies of POTS cohorts have found meaningful overlap with hEDS, which is why this timeline can be useful context rather than a diagnosis (ncbi.nlm.nih.gov).

EDS & hypermobility diagnosis at a glance

There is no single "EDS test" — diagnosis is a staged, clinical process

The search term most people start with — "hypermobility test," "Beighton test," "hEDS test" — makes EDS sound like something one score, swab, or blood draw can settle. It can't. Diagnosis is staged. A clinician first looks for generalized joint hypermobility, often with the Beighton scoring system. Then they ask a larger question: does your whole pattern fit the 2017 international clinical criteria for an Ehlers-Danlos syndrome subtype, or for a related hypermobility condition? If a rarer, genetically defined EDS subtype is suspected, genetic testing may help confirm it. But hypermobile EDS is different: its diagnosis is clinical, because no underlying gene or confirmatory lab marker has been identified for hEDS (nhs.uk).

That is why an appointment can feel broader than "checking for EDS." A knowledgeable clinician is not just measuring how far your thumb, knees, elbows, or spine move. They are reading the pattern: your pain and injury history, skin and tissue signs, family history, fatigue, dizziness, gut symptoms, and whether another condition — arthritis, a different connective-tissue disorder, or something else entirely — explains the picture better. This matters because hypermobility by itself is common, and many people with flexible joints have no symptoms or need no treatment. The point of the process is to separate ordinary flexibility from a connective-tissue disorder that needs management, monitoring, and a care plan (nhs.uk).

The Beighton score — the 9-point hypermobility screen

The Beighton score is the classic bedside screen for generalized joint hypermobility (GJH) — the quick joint-flexibility check behind most searches for a "hypermobility test." It is a 9-point scale built from five maneuvers: each little finger bending back past 90° gives 1 point, each thumb touching the forearm gives 1 point, each elbow extending more than 10° beyond straight gives 1 point, each knee extending more than 10° beyond straight gives 1 point, and placing both palms flat on the floor with the knees fully extended gives 1 point. That makes 8 side-to-side points, plus 1 palms-to-floor point, for a maximum score of 9 (my.clevelandclinic.org).

In the 2017 hEDS criteria, a Beighton score is considered positive for generalized joint hypermobility at ≥6 for prepubertal children and adolescents, ≥5 for pubertal men and women up to age 50, and ≥4 for people older than 50. Those cutoffs come from the 2017 international EDS classification, which revised the clinical criteria for hEDS to better distinguish it from other joint hypermobility conditions (pubmed.ncbi.nlm.nih.gov).

A few things the score does — and doesn't — do:

• It measures flexibility, not a disease. A positive Beighton score tells you your joints move beyond the expected range in the joints being tested. It does not diagnose EDS or hEDS by itself. hEDS is a clinical diagnosis that requires the full 2017 criteria — generalized joint hypermobility, additional systemic/family/pain or instability features, and exclusion of other explanations — and Cleveland Clinic also notes that the Beighton score itself cannot diagnose EDS, Marfan syndrome, or osteogenesis imperfecta (ncbi.nlm.nih.gov).

• The cut-off depends on age. Joint laxity is not stable across life: children tend to be more mobile, and mobility often decreases with age, injury, surgery, pain, or guarding. That is why the 2017 hEDS framework does not use one universal "positive" number for everyone (pmc.ncbi.nlm.nih.gov).

• It can miss "hidden" or historical hypermobility. The Beighton score tests a small set of joints, mostly in the hands, elbows, knees, and spine. It does not directly test many joints people actually struggle with, such as hips, shoulders, ankles, toes, or jaw. If you were much more flexible as a teenager, had surgery, now have pain-limited movement, or feel loose in joints outside the Beighton screen, a clinician may add the 5-point questionnaire and examine other joints instead of treating a low Beighton score as the final word (pmc.ncbi.nlm.nih.gov).

People also search for "Beighton score calculator," "Beighton score pdf," and "Beighton score images." Those can help you understand the movements before an appointment, but a self-scored number is best treated as a conversation-starter: bring it to a clinician along with your joint history, pain pattern, dislocations or subluxations, injuries, skin or scar changes, family history, and anything that has changed over time. The score is a screen. Your body's story is the diagnostic context (my.clevelandclinic.org).

The 5-Part Questionnaire and other self-screens

Not every hypermobility screen needs a clinician in the room. The 5-Part Questionnaire (5PQ) is a short self-report tool: five yes/no questions that ask whether you can, or ever could, put your hands flat on the floor without bending your knees; bend your thumb to your forearm; do the splits or contort your body as a child; had repeated shoulder or kneecap dislocations when younger; or simply think of yourself as "double-jointed." In the original Hakim and Grahame study, answering "yes" to any two of the five questions gave the best combined sensitivity and specificity for detecting hypermobility, and later validation work has supported the 5PQ as a practical way to screen for generalized joint hypermobility when a physical Beighton exam is hard to do (pubmed.ncbi.nlm.nih.gov).

That is why the 5PQ shows up in research as a quick first pass. A 2026 study used exactly this approach, noting that participants were categorized as having hypermobility based on the 5PQ; in that cohort, hypermobility status was determined from a 5PQ assessment rather than from a full diagnostic workup (pmc.ncbi.nlm.nih.gov).

Self-screens are genuinely useful when you are trying to decide whether to raise hypermobility with a doctor. They give shape to something your body may have treated as "normal" for years: joints that go past the usual stopping point, old party tricks that were actually ligament laxity, kneecaps or shoulders that slipped out, floor-touching that never felt like a stretch. But the ceiling is the same as with the Beighton score. The 5PQ can flag a pattern of unusually mobile joints; it cannot tell you why that pattern exists.

So a high 5PQ score, a viral "hypermobility test" video, or a phone-app checklist should be treated as a signal, not a diagnosis. It cannot separate flexible-but-well joints from hypermobility spectrum disorder (HSD), and it cannot diagnose hypermobile Ehlers-Danlos syndrome (hEDS). Current hEDS diagnosis rests on clinical criteria, because hEDS still has no known single molecular cause; people who have symptomatic hypermobility but do not meet hEDS criteria may fall under HSD (ncbi.nlm.nih.gov).

The practical move is simple: if your self-screen is positive, write down the answers, add what your body actually does — pain, sprains, subluxations, dislocations, fatigue, dizziness, gut symptoms, skin or wound-healing clues — and bring that timeline to a clinician. The score opens the conversation. The diagnosis comes from the whole pattern.

The 2017 diagnostic criteria — how hEDS is actually diagnosed

For hypermobile EDS, diagnosis is made against the 2017 international clinical diagnostic criteria — not by one bendy joint, one symptom cluster, or a consumer DNA report. In a large 2026 Mayo Clinic series of 2,451 adults, researchers explicitly studied patients diagnosed with hEDS or HSD using the 2017 criteria and catalogued 122 self-reported symptoms and comorbidities. That matters because hEDS is a whole-body connective-tissue diagnosis with a structured threshold: your joints, skin and soft tissue, pain pattern, family history, and "what else could explain this?" all have to be weighed together (pmc.ncbi.nlm.nih.gov).

The 2017 hEDS criteria have three parts, and all three must be met:

1. Generalized joint hypermobility — usually measured by the Beighton score against an age-adjusted cut-off. In adults, GeneReviews summarizes the 2017 threshold as ≥5 for adolescents who have reached biologic maturity and adults age ≤50, and ≥4 for adults >50; if your Beighton score is one point below the cut-off, a positive 5-point questionnaire can help document historical hypermobility. This is where §2 fits in (ncbi.nlm.nih.gov).

2. Systemic connective-tissue features, family history, and/or musculoskeletal complications — specifically, at least two of Feature A, B, and C. Feature A means five or more systemic features such as unusually soft or velvety skin, mild skin hyperextensibility, unexplained striae, bilateral heel piezogenic papules, recurrent or multiple abdominal hernias, atrophic scarring at two or more sites, pelvic/rectal/uterine prolapse in specific contexts, dental crowding with a high or narrow palate, arachnodactyly, arm-span-to-height ratio ≥1.05, mitral valve prolapse, or aortic root dilatation. Feature B is a first-degree relative who independently meets hEDS criteria. Feature C is pain or instability that fits the hypermobility pattern — for example daily limb pain for at least three months, chronic widespread pain for at least three months, or recurrent atraumatic dislocations / clinically confirmed joint instability (ncbi.nlm.nih.gov).

3. Exclusion of other diagnoses — the clinician has to check for signs that point away from hEDS: unusual skin, ocular, periodontal, vascular, visceral-organ, or skeletal fragility; neuromuscular disorders; other heritable connective-tissue disorders; skeletal dysplasias; and rheumatologic disease that could better explain pain or inflammation. This is the safety step. It is why a good hEDS assessment often feels broader than a "hypermobility test" (ncbi.nlm.nih.gov).

The key point people miss: because hEDS has no confirming gene, meeting these clinical criteria is the diagnosis. There is nothing to "prove it on a lab test" for hEDS specifically. The 2017 international classification states that molecular confirmation is used for the definite diagnosis of EDS subtypes except the hypermobile type, and GeneReviews is even plainer: no underlying genetic etiology has been identified for hEDS, so molecular genetic testing cannot establish the diagnosis (pubmed.ncbi.nlm.nih.gov).

That is also why hypermobility spectrum disorder (HSD) exists as a label: it covers symptomatic hypermobility when the full hEDS criteria are not met and no other more specific diagnosis explains the picture. Practically, this is not a "nothing is wrong" label. HSD can still come with pain, instability, fatigue, autonomic symptoms, GI symptoms, and real functional limits; care often overlaps with hEDS because treatment is guided by the problems your body is actually having, not by a gene result (ncbi.nlm.nih.gov).

Genetic testing — what it confirms, and what it can't

This is where EDS diagnosis splits in two.

For most EDS subtypes, genetic testing can confirm the diagnosis. That means the test is looking for a disease-causing variant in a gene already linked to a specific EDS subtype, not for "loose joints" in general. Classical EDS is usually tied to COL5A1 or COL5A2 and, more rarely, a specific COL1A1 variant; vascular EDS is mainly COL3A1; kyphoscoliotic EDS can involve PLOD1 or FKBP14; arthrochalasia EDS involves COL1A1 or COL1A2; dermatosparaxis EDS involves ADAMTS2; and rarer forms have their own gene targets, such as TNXB, COL1A2, B4GALT7, B3GALT6, SLC39A13, CHST14, DSE, COL12A1, C1R, C1S, ZNF469, or PRDM5, depending on the phenotype and panel used. The 2017 international classification recognized 13 EDS subtypes, and hEDS is the outlier in that map. People searching for "genetic test for heds" or "genetic testing for heds" are usually looking for this kind of clean answer — one gene, one result, one confirmation — but that is not how hEDS works (pubmed.ncbi.nlm.nih.gov).

For hEDS, there is no confirming gene test. hEDS has no identified molecular cause that can be used in routine diagnosis, so it is diagnosed clinically against the 2017 criteria (§4). A negative EDS gene panel does not rule out hEDS; it mainly helps look for other heritable connective-tissue disorders that do have known genes. And a home "EDS DNA kit" cannot diagnose hEDS, because there is currently no molecular genetic test available to establish it. This is one of the most common points of confusion, so it is worth saying plainly: if the question is hEDS, the answer is not in your DNA results — it is in the clinical criteria (ncbi.nlm.nih.gov).

One place genetic testing is genuinely important is vascular EDS (vEDS). vEDS is caused by pathogenic variants in COL3A1, the gene for type III collagen — a collagen your body relies on in blood vessels and hollow organs. That is why vEDS is not just "more flexible joints": it carries a real risk of arterial aneurysm, dissection, or rupture, intestinal rupture, uterine rupture during pregnancy, pneumothorax, and other tissue-fragility complications. If vEDS is suspected because of the clinical picture, family history, or a rupture event, genetic confirmation matters and should be arranged through a geneticist or specialist; GeneReviews states that molecular diagnostic testing of COL3A1 is indicated when vEDS is suspected, and that the diagnosis is established by finding a pathogenic or likely pathogenic COL3A1 variant. This is a medical-priority question, not a home-kit question. Sudden severe unexplained chest, abdominal, or back pain — especially in someone with suspected or confirmed vEDS — needs emergency care (ncbi.nlm.nih.gov).

Why diagnosis takes so long — and who to see

Getting an EDS or hEDS diagnosis is often slow because the signs do not stay in one neat lane. Your joints may be the loudest part, but the story can also include skin, gut, dizziness, faintness, pain, fatigue, migraines, pelvic symptoms, bruising, or family history. Hypermobility itself is common enough to be waved away as "just flexible," while hEDS is diagnosed clinically — there is no confirming gene test to end the argument. That mix is why people can spend years collecting labels before someone connects the pattern. In one 2024 hEDS study, symptoms began at a median age of 10, the first medical evaluation lagged by a median of about 4 years, and the reported time to hEDS diagnosis averaged around 10 years. A qualitative review of adults with hEDS/HSD describes the same diagnostic-odyssey pattern: delayed recognition, fragmented care, and clinicians missing the multisystem shape of the condition (pubmed.ncbi.nlm.nih.gov).

Who actually diagnoses it (`EDS specialist`, `rheumatologist for hypermobility`, `eds clinic`). Primary care can start the process: history, Beighton score, family clues, red flags, and basic exclusions. But if the question is "Do I have hEDS, HSD, or another connective-tissue disorder?", you usually need a clinician who sees this pattern often — commonly a rheumatologist, clinical geneticist, knowledgeable primary-care clinician, or specialized EDS/connective-tissue clinic, depending on your health system and symptoms. hEDS is diagnosed against clinical criteria, and genetic testing is not recommended for typical HSD/hEDS unless another monogenic connective-tissue disorder is suspected; for rarer EDS types, genetics becomes much more important. Physiotherapists experienced in hypermobility are central after diagnosis because the real work is often joint protection, strength, pacing, and safer movement — not proving flexibility over and over. A YouTube Beighton walkthrough or a home DNA kit can help you understand the landscape, but it cannot replace a clinician putting your joints, skin, family history, symptoms, exclusions, and red flags together (pubmed.ncbi.nlm.nih.gov).

Where a wearable fits — and where it doesn't. Welltory can't screen for, test for, or diagnose EDS or hypermobility. But hEDS often travels with POTS and other autonomic problems, and that autonomic layer is where a phone- or watch-based heart-rate and HRV log can add value. If standing, showering, eating, heat, poor sleep, or a hard day makes your heart rate surge, a log turns "I feel awful when I stand" into a dated pattern you can bring to a clinician. That matters because studies have found a real overlap: one POTS cohort found that 31% met hEDS criteria and another 24% had generalized joint hypermobility; a 2025 hEDS autonomic-testing study reported POTS in 33% of tested hEDS patients and widespread mild autonomic failure in many of them. This is a POTS-adjacent contribution to the conversation — context for the autonomic symptoms that may ride with hEDS — not an EDS test (pubmed.ncbi.nlm.nih.gov).

The autonomic overlap — why "bring your data" matters here

A heart-rate and HRV record belongs on an EDS diagnosis page for one simple reason: in real bodies, hypermobility often does not stay "just joints." The same person who can score high on a Beighton screen may also be dealing with dizziness on standing, racing heart, brain fog, heat intolerance, nausea, tremor, fatigue, or near-fainting — the day-to-day pattern clinicians think about when they evaluate dysautonomia/POTS. In a 2026 autonomic-testing study, researchers compared long COVID and ME/CFS patients with healthy controls and with a large hEDS group of 290 patients with hypermobile Ehlers-Danlos syndrome (hEDS), assessed using the same autonomic-lab methods. That does not mean hEDS "is" POTS. It means hEDS is commonly relevant enough in autonomic research to be used as a comparison group, not an afterthought (pmc.ncbi.nlm.nih.gov).

The mast-cell side shows up too. A Johns Hopkins study of people with POTS, neurally mediated hypotension, and/or clinical orthostatic intolerance found that among 188 respondents, 80 (42.6%) reported hives sometimes and 33 (17.6%) reported hives often or always. The authors also found that hives tracked with higher autonomic symptom burden across several symptom domains. This is the hEDS–POTS–mast-cell cluster many patients call the "trifecta," while medical papers more often describe it as a triad — and they also caution that the strength and mechanism of the three-way relationship are still debated (pmc.ncbi.nlm.nih.gov).

None of this is an EDS test. A pulse trend, HRV pattern, smartwatch export, or stand-test log cannot diagnose hEDS, MCAS, or POTS by itself. But it can make the invisible part of your symptom pattern easier to explain: what happens when you stand up, how long your heart rate stays elevated, what triggers crashes, whether symptoms cluster around heat, meals, showers, exercise, sleep loss, or flares. POTS itself is evaluated through symptoms plus heart-rate and blood-pressure changes with standing or tilt testing, so a clear home timeline can help your clinician decide what to test next and what to rule out (my.clevelandclinic.org).

How we made it

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data